| Saketkoo, Lesley Ann |
| Completed | 4 | 246 | US | Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo | Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac | Attention Deficit/Hyperactivity Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | 4 | 123 | US | Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) | Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials | Attention Deficit/Hyperactivity Disorder | 07/25 | 07/25 | | |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
NCT05626751 / 2021-006271-42: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) |
|
|
| Enrolling by invitation | 2 | 246 | Europe, Japan, US, RoW | HZN-825 | Amgen, Horizon Therapeutics USA, Inc, Horizon Therapeuthics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/26 | 09/26 | | |
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation |
|
|
| Active, not recruiting | 2 | 100 | RoW | Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032 | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU | Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers | 07/15 | 05/18 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Active, not recruiting | 1 | 44 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 06/26 | 06/26 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors |
|
|
| Withdrawn | 1 | 10 | RoW | Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib | Center Trials & Treatment, BioGene Pharmaceutical | Advanced or Recurrent Solid Tumors, Breast Neoplasm | 12/23 | 01/24 | | |
|
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 12/24 | 04/25 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Recruiting | 1 | 21 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 06/26 | 08/31 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus |
|
|
| Terminated | N/A | 2432 | US, RoW | | Center Trials & Treatment, Oleg Martynenko | COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE) | 03/23 | 03/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 01/25 | 01/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Recruiting | N/A | 350 | US | Veye Lung nodules | Aidence | Lung; Node | 07/21 | 07/21 | | |
| Khan, Arifulla |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Enrolling by invitation | 3 | 285 | Europe, Canada, US | Experimental: ALZ-801 | Alzheon Inc. | Early Alzheimer's Disease | 12/25 | 01/26 | | |
| Active, not recruiting | 3 | 1083 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 05/25 | 05/25 | | |
| Recruiting | 3 | 300 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Chronic Migraine | 07/25 | 03/26 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
| Recruiting | 3 | 325 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Episodic Migraine | 11/25 | 11/26 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
| Active, not recruiting | 2/3 | 225 | Canada, US | Piromelatine 20 mg, Neu-P11, Placebo | Neurim Pharmaceuticals Ltd., Syneos Health | Alzheimer's Disease | 06/25 | 06/25 | | |
| Completed | 2/3 | 554 | US | ATH-1017, Placebo | Athira Pharma | Alzheimer Disease, Dementia of Alzheimer Type | 07/24 | 07/24 | | |
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention |
|
|
| Terminated | 2/3 | 538 | US | BHV-3500 (zavegepant), Placebo | Pfizer | Migraine | 03/24 | 03/24 | | |
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain |
|
|
| Completed | 2 | 147 | US | LY3857210, Placebo | Eli Lilly and Company | Osteoarthritis | 06/23 | 06/23 | | |
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain |
|
|
| Completed | 2 | 138 | US | LY3857210, Placebo | Eli Lilly and Company | Chronic Low-back Pain | 06/23 | 06/23 | | |
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). |
|
|
| Completed | 2 | 131 | US | LY3857210, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathic Pain | 07/23 | 08/23 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
NCT05066672: Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression |
|
|
| Recruiting | 2 | 400 | US | NV-5138, SPN820, matched placebo, placebo, PBO | Navitor Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc. | Treatment Resistant Depression | 12/24 | 12/24 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
| Wright, Anne |
| Recruiting | 4 | 600 | Europe, Canada, US, RoW | Rimegepant, Placebo | Pfizer, Pfizer | Migraine | 05/25 | 08/25 | | |
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis |
|
|
| Terminated | 2 | 229 | Canada, US | RPT193, Placebo | RAPT Therapeutics, Inc. | Atopic Dermatitis | 05/24 | 05/24 | | |
NCT04147793: Case Control Study to Investigate the Use of Urethral Pressure Profile Measurement in Children |
|
|
| Not yet recruiting | N/A | 36 | Europe | | King's College London | Dysfunctional Voiding, Stress Incontinence, Urinary | 03/27 | 03/28 | | |
| Puente, Orlando |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 2/3 | 225 | Canada, US | Piromelatine 20 mg, Neu-P11, Placebo | Neurim Pharmaceuticals Ltd., Syneos Health | Alzheimer's Disease | 06/25 | 06/25 | | |
| Dennis, Patrick |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Completed | 3 | 275 | US | Digital ACT, Digital Symptom Tracker | Swing Therapeutics, Inc. | Fibromyalgia | 05/23 | 05/23 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt |
|
|
| Active, not recruiting | 2 | 150 | US | Enobosarm, Semaglutide, Wegovy | Veru Inc. | Muscle Loss, Obesity | 12/24 | 04/25 | | |
| Recruiting | 2 | 1380 | NA | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity |
|
|
| Recruiting | 2 | 350 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity | 01/26 | 10/26 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
| Jackson, Sarah A |
| Not yet recruiting | 4 | 160 | US | Atomoxetine, Strattera, Placebo | VA Office of Research and Development, Medical University of South Carolina | Posttraumatic Stress Disorder With Attention Defic | 07/28 | 10/28 | | |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
| Withdrawn | 2 | 1 | US | Varenicline, Chantix, Placebo | VA Office of Research and Development | Tobacco Use Disorder, Cannabis Use Disorder | 07/24 | 07/24 | | |
NCT06494319: Development Of a Virtual Stress Inoculation Training (SIT) Platform and Mobile Health App |
|
|
| Recruiting | N/A | 20 | US | Stress NAVIGATOR (Mobile Health Application), SIT NAVIGATOR | The University of Texas Health Science Center, Houston | PTSD, Trauma and Stressor Related Disorders, Traumatic Brain Injury | 06/25 | 06/25 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study |
|
|
| Recruiting | N/A | 400 | Europe, US, RoW | AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy | Ancora Heart, Inc. | Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy | 12/26 | 12/30 | | |
| Recruiting | N/A | 100 | Europe | HPV DNA methylation assay | Queen Mary University of London, National Cancer Institute (NCI) | HPV Infection | 02/25 | 10/28 | | |
NCT06656780: Stress Inoculation Training (SIT): An Evidence-Based, Military Aligned Psychological Performance and Health Sustainment Prototype |
|
|
| Not yet recruiting | N/A | 120 | US | SIT, DCA-FF | The University of Texas Health Science Center, Houston, Department of Defense / Congressionally Mandated Research Program (CDMRP) | Stress, Psychological | 06/27 | 06/27 | | |
| Recruiting | N/A | 1500 | US | Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF) | Impulse Dynamics | Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure | 02/25 | 02/26 | | |
| Not yet recruiting | N/A | 23520 | US | PCP-Facing Tools, LCS team population management tools | VA Office of Research and Development | Lung Cancer, Lung Cancer Screening | 03/29 | 09/29 | | |
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR |
|
|
| Recruiting | N/A | 300 | Europe, US | Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication | Cardiac Dimensions, Inc. | Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases | 12/26 | 12/30 | | |
GAM, NCT05628324: EMG-Controlled Game to Retrain Upper Extremity Muscle Activation Patterns Following Stroke |
|
|
| Recruiting | N/A | 62 | US | practice muscle activation patterns, task practice | VA Office of Research and Development | Stroke | 03/27 | 03/27 | | |
| Not yet recruiting | N/A | 24 | US | repetitive transcranial magnetic stimulation--Active, rTMS, repetitive transcranial magnetic stimulation--Sham | VA Office of Research and Development | Spinal Cord Injuries, Depression, Depressive Disorder, Major | 04/27 | 10/27 | | |
| Tate, Melita |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Completed | 3 | 275 | US | Digital ACT, Digital Symptom Tracker | Swing Therapeutics, Inc. | Fibromyalgia | 05/23 | 05/23 | | |
| Recruiting | 2 | 1380 | NA | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
| Trier, Miranda |
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination |
|
|
| Recruiting | 3 | 800 | US | CHIKV VLP vaccine booster, PXVX0317, Placebo booster | Bavarian Nordic | Chikungunya Virus Infection | 04/28 | 08/28 | | |
| Simon, Caitlin |
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention |
|
|
| Terminated | 2/3 | 538 | US | BHV-3500 (zavegepant), Placebo | Pfizer | Migraine | 03/24 | 03/24 | | |
| Giorlando, Katie |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
NCT05626751 / 2021-006271-42: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) |
|
|
| Enrolling by invitation | 2 | 246 | Europe, Japan, US, RoW | HZN-825 | Amgen, Horizon Therapeutics USA, Inc, Horizon Therapeuthics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/26 | 09/26 | | |
| Dunbar, John |
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) |
|
|
| Completed | 3 | 496 | US | Lorecivivint, SM04690, Placebo, Vehicle | Biosplice Therapeutics, Inc., NBCD A/S | Knee Osteoarthritis | 02/24 | 02/24 | | |
| Dwarika, Matthew |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
RESET-Myositis, NCT06154252: an Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy |
|
|
| Recruiting | 1/2 | 18 | US | CABA-201 following preconditioning with fludarabine and cyclophosphamide | Cabaletta Bio | Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy | 07/28 | 07/28 | | |
| Mister, Reggie |
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
|
|
| Recruiting | 2/3 | 390 | Europe, US, RoW | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Focal Epilepsy | 08/25 | 09/25 | | |
| Yates, Erin |
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
|
|
| Recruiting | 2/3 | 390 | Europe, US, RoW | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Focal Epilepsy | 08/25 | 09/25 | | |
